BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 26289459)

  • 1. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
    Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
    Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in chromatin machinery and pediatric high-grade glioma.
    Lulla RR; Saratsis AM; Hashizume R
    Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated chromatin remodeling in the pathobiology of brain tumors.
    Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
    Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone modifications and cancer.
    Sawan C; Herceg Z
    Adv Genet; 2010; 70():57-85. PubMed ID: 20920745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between different epigenetic modifications and mechanisms.
    Murr R
    Adv Genet; 2010; 70():101-41. PubMed ID: 20920747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer.
    Luan J; Chu Z; Chandra J; Zhang P
    Curr Protein Pept Sci; 2016; 17(5):455-62. PubMed ID: 26796303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone modification: cause or cog?
    Henikoff S; Shilatifard A
    Trends Genet; 2011 Oct; 27(10):389-96. PubMed ID: 21764166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trials with 'epigenetic' drugs: an update.
    Nebbioso A; Carafa V; Benedetti R; Altucci L
    Mol Oncol; 2012 Dec; 6(6):657-82. PubMed ID: 23103179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin regulators with tumor suppressor properties and their alterations in human cancers.
    Shu XS; Li L; Tao Q
    Epigenomics; 2012 Oct; 4(5):537-49. PubMed ID: 23130835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. THE ANALYSIS OF LGI1 GENE EPIGENETIC ALTERATIONS BY MEANS OF POSTTRANSLATIONAL H3 HISTONE MODIFICATIONS IN MALIGNANT GLIOMAS.
    Semenova EV; Volnitsky AV; Filatov MV
    Tsitologiia; 2016; 58(5):335-9. PubMed ID: 30188624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulators and histone modification.
    Imhof A
    Brief Funct Genomic Proteomic; 2006 Sep; 5(3):222-7. PubMed ID: 16951415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing epigenetic domains via chromatin-bound histone modifiers.
    Erdel F; Müller-Ott K; Rippe K
    Ann N Y Acad Sci; 2013 Dec; 1305():29-43. PubMed ID: 24033539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromatin remodeling, cancer and chemotherapy.
    Dey P
    Curr Med Chem; 2006; 13(24):2909-19. PubMed ID: 17073637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.